Department of Psychiatry
Penn Behavioral Health

Translational Neuroscience Program

subpage feature

Siegel Lab Publications

Click Here for the Most Recent Lab Publications

Electrophysiological and behavioral responses to ketamine in mice with reduced Akt1 expression. Featherstone RE, M Tatard-Leitman V, Suh JD, Lin R, Lucki I, Siegel SJ. Psychopharmacology (Berl). 2013 Feb 8. [Epub ahead of print] PMID: 23392353

Loss of CDKL5 disrupts kinome profile and event-related potentials leading to autistic-like phenotypes in mice. Wang IT, Allen M, Goffin D, Zhu X, Fairless AH, Brodkin ES, Siegel SJ, Marsh ED, Blendy JA, Zhou Z. Proc Natl Acad Sci U S A. 2012 Dec 26;109(52):21516-21.

Electroencephalographic changes following direct current deep brain stimulation of auditory cortex: a new model for investigating neuromodulation. De Rojas JO, Saunders JA, Luminais C, Hamilton RH, Siegel SJ. Neurosurgery. 2013 Feb;72(2):267-75

Delivery systems and dosing for antipsychotics. Rabin CR, Siegel SJ. Handb Exp Pharmacol. 2012;(212):267-98.

Nicotine receptor subtype-specific effects on auditory evoked oscillations and potentials. Featherstone RE, Phillips JM, Thieu T, Ehrlichman RS, Halene TB, Leiser SC, Christian E, Johnson E, Lerman C, Siegel SJ. PLoS One. 2012;7(7):e39775.

The electrophysiological signature of motivational salience in mice and implications for schizophrenia. Moessnang C, Habel U, Schneider F, Siegel SJ. Neuropsychopharmacology. 2012 Dec;37(13):2846-54.

GABAB-mediated rescue of altered excitatory-inhibitory balance, gamma synchrony and behavioral deficits following constitutive NMDAR-hypofunction. Gandal MJ, Sisti J, Klook K, Ortinski PI, Leitman V, Liang Y, Thieu T, Anderson R, Pierce RC, Jonak G, Gur RE, Carlson G, Siegel SJ. Transl Psychiatry. 2012 Jul 17;2:e142.

NMDA antagonist MK801 recreates auditory electrophysiology disruption present in autism and other neurodevelopmental disorders. Saunders JA, Gandal MJ, Roberts TP, Siegel SJ. Behav Brain Res. 2012 Oct 1;234(2):233-7.

Mice with reduced NMDA receptor expression: more consistent with autism than schizophrenia? Gandal MJ, Anderson RL, Billingslea EN, Carlson GC, Roberts TP, Siegel SJ. Genes Brain Behav. 2012 Aug;11(6):740-50.

Subchronic ketamine treatment leads to permanent changes in EEG, cognition and the astrocytic glutamate transporter EAAT2 in mice. Featherstone RE, Liang Y, Saunders JA, Tatard-Leitman VM, Ehrlichman RS, Siegel SJ. Neurobiol Dis. 2012 Sep;47(3):338-46.

Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier. Makadia HK, Siegel SJ. Polymers (Basel). 2011 Sep 1;3(3):1377-1397.

Nicotine normalizes event related potentials in COMT-Val-tg mice and increases gamma and theta spectral density. Cao YA, Featherstone RE, Gandal MJ, Liang Y, Jutzeler C, Saunders J, Tatard-Leitman V, Chen J, Weinberger DR, Lerman C, Siegel SJ. Behav Neurosci. 2012 Apr;126(2):332-43

MeCP2+/- mouse model of RTT reproduces auditory phenotypes associated with Rett syndrome and replicate select EEG endophenotypes of autism spectrum disorder. Liao W, Gandal MJ, Ehrlichman RS, Siegel SJ, Carlson GC. Neurobiol Dis. 2012 Apr;46(1):88-92.

NMDA antagonists recreate signal-to-noise ratio and timing perturbations present in schizophrenia. Saunders JA, Gandal MJ, Siegel SJ. Neurobiol Dis. 2012 Apr;46(1):93-100..

Rett syndrome mutation MeCP2 T158A disrupts DNA binding, protein stability and ERP responses. Goffin D, Allen M, Zhang L, Amorim M, Wang IT, Reyes AR, Mercado-Berton A, Ong C, Cohen S, Hu L, Blendy JA, Carlson GC, Siegel SJ, Greenberg ME, Zhou Z. Nat Neurosci. 2011 Nov 27;15(2):274-83.

mGluR5-antagonist mediated reversal of elevated stereotyped, repetitive behaviors in the VPA model of autism. Mehta MV, Gandal MJ, Siegel SJ. PLoS One. 2011;6(10):e26077.

Dysbindin-1 mutant mice implicate reduced fast-phasic inhibition as a final common disease mechanism in schizophrenia. Carlson GC, Talbot K, Halene TB, Gandal MJ, Kazi HA, Schlosser L, Phung QH, Gur RE, Arnold SE, Siegel SJ. Proc Natl Acad Sci U S A. 2011 Oct 25;108(43):E962-70..

What can we expect from long-acting formulations for schizophrenia? Siegel SJ. Curr Psychiatry Rep. 2011 Aug;13(4):243-4.

Gamma synchrony: towards a translational biomarker for the treatment-resistant symptoms of schizophrenia. Gandal MJ, Edgar JC, Klook K, Siegel SJ. Neuropharmacology. 2012 Mar;62(3):1504-18.